The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.
Yusuke KimuraRena KanekoYuichiro YanoKentaro HiraoTakashi IkeharaHidenari NagaiYuzuru SatoYoshinori IgarashiPublished in: Asian Pacific journal of cancer prevention : APJCP (2020)
With an array of therapeutic options currently available, it is important to determine the efficacy of different multimodal strategies, such as sorafenib combined TACE, for patients with unresectable HCC.